Frazier Life Sciences Management L.P. lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) by 7.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,381,090 shares of the company’s stock after purchasing an additional 500,000 shares during […]
/PRNewswire/ Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral.
/PRNewswire/ Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral.